Company Performance Metrics
- Katarzyna Kolacz: President
Cellex, an innovative Small and Medium Enterprise (SME) founded in 2018, specializes in designing and manufacturing advanced bioreactors for cell culture, as well as developing state-of-the-art digital twin software for bioprocesses. Headquartered in Rome, with a subsidiary in Wageningen, Netherlands, Cellex is entering the scale-up phase after
securing multiple grants and raising capital from investors. With a solid foothold in the biotech industry, Cellex aims to revolutionize the production of cell-derived drugs, cultivated meat, and tissue engineering through its innovative hardware and software solutions.
Key Products • SUSPENCE®®: A patented suspension bioreactor designed for cell culture with high efficiency and reduced operational costs. • BioAxFlow: A multi-tissue bioreactor aimed at tissue engineering and cultivated meat production. • BioDigiTwin: A digital twin software that simulates and optimizes bioprocesses, automating control and enhancing productivity.
Markets and Target Segments • Biopharmaceuticals: SUSPENCE® bioreactors to produce vaccines and monoclonal antibodies. • Tissue Engineering: BioAxFlow bioreactors for tissue substitutes, in vitro tissue models, cultivated meat, and other applications. • Digital Twins for Bioprocesses: BioDigiTwin for real-time control and cost optimization of bioprocesses.
